Gut bacteria may shield nerves from chemo damage – a trial puts it to the test

NCT ID NCT07733817

Not yet recruiting Symptom relief Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This phase III trial tests whether a daily probiotic supplement, OXXYSLAB®, can reduce peripheral neuropathy—nerve damage causing pain and numbness—in people with stage III colon cancer receiving oxaliplatin-based chemotherapy (FOLFOX or XELOX). About 130 participants will take either the probiotic or a placebo starting one week before their first chemo cycle and continuing until one week after the last. The study tracks how many develop moderate-to-severe nerve symptoms, aiming to see if a simple gut intervention can ease a common, debilitating side effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a multi-strain probiotic supplement called OXXYSLAB®
What this could lead to: If effective, this probiotic could offer a simple, non-drug way to reduce painful nerve damage caused by chemotherapy, improving quality of life during colon cancer treatment.
What could go wrong: This is a relatively small phase III trial, and the effect may be modest or not clinically meaningful. Probiotics can also cause digestive side effects or interact with the gut microbiome in unpredictable ways.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colonic neoplasm neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON ADENOCARCINOMA NEUROPATHIC PAIN

Contacts and locations

Locations

CH

Saint-Lô, France
CHU

Caen, France
CHU

Lille, France
CHU

Rouen, France
Centre François Baclesse

Caen, Centre François Baclesse, 14076, France
Centre Oscar Lambret

Lille, France
Ch Aunay-Bayeux

Bayeux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.